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1. Introduction
In 2003, the South African Heart Association (SA Heart) and the Lipid 
and Atherosclerosis Society of Southern Africa (LASSA) officially 
adopted the European Guidelines for the Prevention of Cardiovascular 
Disease[1] to replace the South African Lipid Guidelines published 
in 2000.[2] Based on the 2011 publication of the European Society 
of Cardiology (ESC)/European Society of Atherosclerosis (EAS) 
Guideline for the Management of Dyslipidaemias,[3] a comprehensive 
South African Dyslipidaemia Guideline Consensus Statement was 
published in 2012.[4] When the European document was revised 
in 2016,[5] it was necessary to update the South African Guideline 
Consensus Statement to ensure that it is based on the most recent 
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South Africa (SA) is home to a heterogeneous population with a wide range of cardiovascular risk factors. Cholesterol reduction in 
combination with aggressive management of modifiable risk factors, including nutrition, physical activity, blood pressure and smoking, can 
help to reduce and prevent morbidity and mortality in individuals who are at increased risk of cardiovascular events. This updated consensus 
guide to management of dyslipidaemia in SA is based on the updated European Society of Cardiology and European Atherosclerosis Society 
dyslipidaemia guidelines published in 2016. For individuals who are not considered to be at high or very high cardiovascular risk, the 
decision whether to treat and which interventional strategy to use is based on a cardiovascular risk score calculated using total cholesterol, 
high-density lipoprotein cholesterol (HDL-C), gender, age and smoking status. The cardiovascular risk score refers to the 10-year risk of 
any cardiovascular event and includes 4 categories of risk (low, moderate, high and very high). People with established cardiovascular 
disease, diabetes mellitus, chronic kidney disease and genetic or severe dyslipidaemias are considered to already be at high or very high risk 
and do not require risk scoring. Therapeutic lifestyle change is the mainstay of management for all patients. The need for and intensity of 
drug therapy is determined according to baseline low-density lipoprotein (LDL-C) levels and the target LDL-C concentration appropriate 
to the individual. LDL-C treatment targets are based on pre-treatment risk and are as follows: <3 mmol/L in low- and moderate risk cases; 
<2.5 mmol/L and a reduction of at least 50% if the baseline concentration is 2.5 - 5.2 mmol/L in high-risk cases; and <1.8 mmol/L and a 
reduction of at least 50% if the baseline concentration is 1.8 - 3.5 mmol/L in very high-risk cases. A statin is usually recommended first-line; 
the specific agent is based on the required degree of cholesterol reduction, comorbidities and co-prescribed medication. 
Special attention should be paid to children with a family history of genetic or severe dyslipidaemia, who should be screened for 
dyslipidaemia from 8 years of age. In SA, HIV infection is not considered to be a significant cardiovascular risk factor and treatment 
recommendations for HIV-positive individuals are the same as for the general population, with careful choice of pharmacotherapy to avoid 
potential adverse drug-drug interactions. The benefit of statins in individuals older than 70 years is uncertain and clinical judgement should 
be used to guide treatment decisions and to avoid side-effects and overmedication in this group.
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and best available data. Additionally, it is necessary to place the latest 
international guidelines in a context that is relevant to South Africans 
and to make the main recommendations of the guideline available in 
a succinct and accessible format. 
All ESC guidelines are developed using a rigorous, standardised 
and transparent process. This process involves selection of a task 
force that includes members from multiple relevant societies, careful 
review and grading of evidence, consensus achievement and external 
peer review. All guidelines are reviewed annually by the task force 
chairman and a selected expert group who decide whether there is 
sufficient new evidence that would influence the recommendations 
made. All guidelines are formally revised at least once every 5 years. 
Further details on the ESC guideline development process can 
be found at https://www.escardio.org/Guidelines/Clinical-Practice-
Guidelines/Guidelines-development/Writing-ESC-Guidelines. 
The 2018 South African update aims to ensure and promote 
current best management of dyslipidaemia in South Africa (SA). We 
strongly recommend that these guidelines be adopted by all South 
African healthcare professionals and healthcare funders in both the 
private and public sectors. The South African Guideline Consensus 
Statement is adopted from the ESC guidelines and will be updated 
in concert with their guideline updates. Because the guidelines on 
which this consensus statement is based were subjected to a rigorous 
process of external peer review this statement has not been submitted 
for further external peer review. Readers that are interested in the 
full ESC guidelines and the stringent review process followed, should 
refer to the full text of the ESC guidelines that reviews the evidence 
base for each recommendation in detail and grades the strength of 
each recommendation.[6] As our aim was to keep this statement short 
and accessible, in contrast to the 78 pages of the full guideline, we 
have not included all the information in the consensus statement. 
Our recommendations are accepted to be best-practice care and 
are based on the current available evidence. In their purest form, 
guidelines do not consider the cost of therapeutic decisions. However, 
one cannot be blind to the financial implications in the SA context. 
The effectiveness of lipid-lowering therapy is well established, but the 
raw cost of the drugs can vary according to individual, institutional, 
provider and governmental factors. It is not possible for this writing 
committee to take all these factors into account when compiling 
this consensus statement. It is therefore up to each participant in 
the healthcare system to decide what is ‘affordable’ or not. Taking 
the latter into account will enable a rational decision as to the cost 
effectiveness of therapy (i.e. in the high- and very high-risk secondary 
prevention patient as opposed to the lower-risk primary prevention 
scenario). However, at all times a decision with regard to cost should 
not detract from the ultimate goal of reducing the actual burden of 
cardiovascular disease. 
The INTERHEART study conducted in 52 countries throughout 
Africa, Asia, Australia, Europe, the Middle East, and North and 
South America showed that more premature acute myocardial 
infarctions occur in sub-Saharan Africa than anywhere else.[7,8] This 
statistic underscores a lack of prevention, early detection and effective 
management of cardiovascular (CV) risk factors in the countries of 
this region in general.[7] In particular, South Africans are at high 
risk of cardiovascular disease (CVD), having among the highest 
prevalences of obesity, undiagnosed diabetes mellitus, smoking and 
high cholesterol in Africa.[9,10] In some communities, type 2 diabetes is 
remarkably common. Age-standardised prevalences are estimated at 
13% in Asian Indians, 11% in coloured (mixed ancestry) communities 
(26% in the Western Cape), and up to 8% among urban black South 
Africans.[11] Familial hypercholesterolaemia (FH), characterised by 
markedly elevated low-density lipoprotein cholesterol (LDL-C) and 
premature CVD is an inherited autosomal dominant disorder that 
is more than 3 times more common among certain South African 
populations than in other global populations.[12,13]
The SA population is multi-ethnic, with considerable 
sociodemographic and economic diversity and a large range of 
cultures and lifestyles at different stages of epidemiological transition. 
This heterogeneity is reflected also in levels of CVD risk, which vary 
considerably depending on race group, socioeconomic status and 
education level. For example, among black South Africans, CVD 
risk increases with years of formal education and income level, 
whereas an opposite trend is evident among the coloured population 
and those of European descent.[7] Although the mortality rates 
attributable to CVD have traditionally been lower among black South 
Africans than in the other racial groups, the prevalence of CVD and 
the incidence of premature death is increasing among both rural and 
urban communities and across the socioeconomic spectrum in this 
population. Factors that account for this include demographic change 
predominantly driven by an increase in older people who are at 
greatest risk of developing chronic diseases, increasing urbanisation 
and adoption of an unhealthy lifestyle, and inequalities in access to 
healthcare.[7,10,14,15] 
Consequently, the timely institution of lifestyle modification, early 
diagnosis and effective management of CVD risk factors are essential 
to prevent the impending epidemic of CVD in SA.[10] 
Dyslipidaemia is an important target for intervention in all 
population groups. Data collected up until 2000 indicated that 28% 
of black South Africans and >80% of white, coloured and Indian 
adults >30 years of age have serum total cholesterol (TC) levels 
≥5 mmol/L. Although there was marked variation between population 
groups, it was estimated that more than half of all ischaemic heart 
disease (IHD) and more than one-quarter of all ischaemic strokes 
were associated with high serum cholesterol levels.[16]
2. Screening
In the absence of risk factors for CVD, all individuals should be 
screened, preferably with a full lipogram or at least TC or LDL-
C, from the age of 40 years. However, earlier screening during 
infancy, before puberty or at around 20 years is indicated for certain 
individuals, depending on genetics, family history and other cardiac 
risk factors (Table 1).
Screening for FH is recommended for all potentially affected 
relatives of patients with severe dyslipidaemia, and testing should 
be extended, in turn, to relatives of each one of those in whom FH 
is diagnosed (cascade screening).[17] Screening should start before 
puberty (around 8 years) in children of affected families. Initial 
screening is based on clinical evaluation and LDL-C sampling. 
Genetic screening for specific mutations in FH-associated genes is 
available at some private laboratories and university research clinics, 
and may be useful in certain families. However, a negative genetic test 
does not exclude FH.
Individuals identified with the FH genotype and/or phenotype 
who have very raised LDL-C (>10 mmol/L) or who do not 
respond adequately to treatment with a potent statin (atorvastatin 
or rosuvastatin) plus ezetimibe should be referred for specialist 
evaluation where possible.
3. Laboratory investigations of 
dyslipidaemia 
3.1 Initial consultation: Screening and assessment of CV 
risk using Framingham tables
Estimating CV risk with the Framingham tables is used to guide 
clinical decisions for primary prevention only and patients who have 
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already presented with features of atherosclerosis and cardiovascular 
events are not scored. In addition to TC and high-density lipoprotein 
cholesterol (HDL-C), the Framingham Score requires the patient’s 
age, blood pressure (BP) (on or off antihypertensive therapy) and 
smoking status.
Although a finger-prick test of TC is the least expensive and easiest 
measurement of blood cholesterol, if it is elevated (>5 mmol/L) then, 
in order to use the Framingham tables (Appendix 1), a full lipogram 
is required. 
3.2 Timing of testing at diagnosis
A full lipogram (TC, HDL-C, LDL-C and triglycerides (TG)) is 
recommended for initial diagnosis of dyslipidaemia. Although it was 
previously recommended that blood samples for lipid estimation 
be drawn in the fasting state, recent evidence indicates that fasting 
and non-fasting blood samples yield similar results for TC, LDL-C 
and HDL-C and are comparable for estimation of CV risk.[18,19] 
To improve patient compliance and encourage measurement of 
plasma lipids at the clinic visit, non-fasting samples may be used 
for screening, diagnosis and monitoring of treatment effect. Blood 
samples reported as ‘lipaemic’ by the laboratory indicate elevated TG, 
which requires further investigation or referral as necessary. TG levels 
are affected following a meal and, providing metabolism of TG-rich 
proteins is normal, TGs may vary by ~0.3 mmol/L depending on the 
interval between the last meal and when the blood sample is taken. 
Therefore, a TG level that should be flagged as abnormally raised is 
≥2 mmol/L in a non-fasting sample and ≥1.7 mmol/L in a fasting 
sample. A TG level >5 mmol/L in a non-fasting sample requires a 
confirmatory fasting sample. 
3.3 Follow-up consultation: Assessing treatment goals 
and monitoring effectiveness of therapy
After initiating therapeutic lifestyle change (TLC) alone, follow-
up testing of plasma lipids should be performed 6-monthly. 
After initiating pharmacotherapy, changing the dose or changing 
medication for dyslipidaemia, testing should be repeated at 8 (±4) 
weeks. Thereafter, once the patient is at goal, testing should be 
repeated 6-monthly.
3.3.1 Low-density lipoprotein cholesterol (LDL-C)
Although TC and HDL-C are required to initially score individuals 
for primary prevention, once the score has been completed, the 
pretreatment LDL-C level is used to assign the correct statin dose to 
achieve the LDL-C goal as described in Table 4.
LDL-C may be measured directly or calculated from the Friedewald 
equation (provided the TGs do not exceed 4.5 mmol/L):
[LDL-C] = [TC] - [HDL-C] – [TG/2.2] (all units in mmol/L).
3.3.2 Full lipogram
In patients with pure hypercholesterolaemia, LDL-C alone is adequate 
for follow-up, but a full lipogram is recommended where increased 
LDL-C is not the only abnormality in the lipid profile. 
3.3.3 Total cholesterol as a surrogate for LDL-C
In patients where LDL-C has been used to initiate and monitor 
treatment, once the relationship between on-treatment TC and 
LDL-C is known, monitoring TC only is an alternative if LDL-C 
measurements are not readily available. However, it must be borne 
in mind that measuring TC alone is not optimal and it is preferable 
to measure LDL-C. Nevertheless, finger-prick testing of TC may be 
used as an alternative for monitoring treatment efficacy if there are 
cost constraints or if there is difficulty in obtaining either direct or 
indirect LDL-C values. 
• When TC = 4.5 mmol/L, the approximate value of LDL-C = 
2.5 mmol/L.
• When TC = 4.0 mmol/L, the approximate value of LDL-C = 
1.8 mmol/L.
If an LDL-C measurement is unavailable and TC values remain 
uncontrolled, the patient should be referred to a higher level of 
care.
3.4 Point-of-care finger-prick testing
Various point-of-care (POC) testing devices are available that can 
measure a variety of lipid parameters, ranging from TC alone to a full 
lipogram. Where finger-prick testing is performed, the facility should 
ensure that adequate quality controls are in place, that the test strips 
and devices are stored under appropriate conditions of temperature, 
humidity and light, and that precautions are taken to perform the 
test properly, with an adequate blood sample volume and without 
contamination.[20] The finger should not be squeezed or ‘milked’, as 
this will give inaccurate results. 
It must be borne in mind that machines that are not approved by 
the Food and Drug Administration (FDA) or European Medicines 
Agency (EMA) may not be accurate and may under-read. Therefore, 
it is recommended that only suitably approved devices are used and 
that POC devices at each centre be calibrated regularly according to 
the manufacturer’s instructions.
Table 1. Recommended ages to start screening for dyslipidaemia
From age 8 years From age 20 years From age 40 years
1. Family history of severe dyslipidaemia
2. Relative of subject with FH (if both 
parents have FH, testing should be 
undertaken within the first 6 months of life 
to identify infants with homozygous FH)
Presence of CV risk factors:
1. Hypertension and/or on antihypertensive 
medication
2. Smoking: any smoking
3. Family history of premature CVD in 
first degree relative (male ≤55 years of age; 
female ≤65 years of age) 
4. BMI ≥30 kg/m2 or waist circumference 
>94 cm (men), >80 cm (women)
5. Autoimmune chronic inflammatory 
disease, e.g. rheumatoid arthritis, systemic 
lupus erythematosus, psoriasis
6. CKD
All other individuals 
(asymptomatic adults without evidence of CVD, 
diabetes, CKD or FH)
FH = familial hypercholesterolaemia; CV = cardiovascular; CVD = cardiovascular disease; CKD = chronic kidney disease; BMI = body mass index.
978       November 2018, Vol. 108, No. 11 (Part 2)
GUIDELINE
POC finger-prick testing is appropriate for population screening. 
However, POC testing is not appropriate to commit a patient to a 
lifetime of therapy, nor is it adequate to diagnose dyslipidaemias 
in high-risk individuals or those with a family history of FH. 
These patients require formal assessment. Similarly, where a 
screening finger-prick TC measurement is high (>5 mmol/L), 
patients should be referred back to their doctor for a full laboratory-
performed lipogram and formal cardiovascular risk assessment. 
Because underestimation of LDL-C and inappropriately low results 
are a concern, TC <3.0 mmol/L on a finger-prick test should 
be confirmed with a laboratory result. Finger-prick testing that 
measures TC alone will not detect raised triglycerides.
4. Diagnosis of familial 
hypercholesterolaemia
There are a number of different approaches to the diagnosis of FH, 
including the Dutch Lipid Clinic criteria and the Simon Broome 
criteria, among others.[21] The Simon Broome diagnostic criteria are 
easier to use (Table 2).
5. Secondary causes of dyslipidaemia
Dyslipidaemia may occur in response to another condition or 
medication (Table 3) and suspicion of secondary dyslipidaemia 
should prompt appropriate investigations and treatment. 
Importantly, hypothyroidism, which is easily missed, should be 
considered before committing a patient to a lifetime of therapy for 
dyslipidaemia, and measurement of thyroid stimulating hormone 
(TSH) is recommended where appropriate. Diabetes can cause 
severe hypertriglyceridaemia if there is an otherwise mild genetic 
variant in triglyceride metabolism.
6. Cardiovascular risk scoring
6.1 Very high risk and high risk individuals do not need 
to be scored
Individuals who are considered to be at very high risk or high risk 
of cardiovascular events are listed in Table 5. Patients in this group 
do not require Framingham cardiovascular risk scoring, because the 
algorithm will underestimate the risk in these settings. 
6.1.1 Other individuals at high risk and very high risk
Individuals who are regarded at high or very high risk according to 
their score on the Framingham 10-year risk tables are
• score >15% but <30% (high risk)
• score >30% (very high risk)
6.2 How to use the Framingham Risk Charts
Management decisions for patients who do not fall into the very high- 
or high risk categories based on clinical evaluation are guided by 
risk scoring algorithms. The European guidelines use the Systematic 
Coronary Risk Estimation (SCORE) system to estimate CV risk. 
Because this scoring system is based on a fatal CV risk endpoint in 
a European population, it may not accurately reflect coronary risk 
in South Africa. While it is recognised that it would be impossible 
to accurately estimate risk in all SA subpopulations with a single 
data set, the Framingham risk tables, which provide an estimate of 
the 10-year risk of total CVD (fatal and non-fatal coronary events, 
cerebrovascular and peripheral arterial disease, and heart failure) 
have been validated in white and black populations in the USA and are 
applicable to other culturally diverse populations.[24,25] Consequently, 
this approach is considered to be more appropriate for the multi-
ethnic SA society. Nevertheless, it should be borne in mind that these 
Table 2. Simon Broome criteria for diagnosis of familial hypercholesterolemia (FH)[21-23] 
Definite FH
1. Severely elevated cholesterol* and tendinous xanthomata in the patient or a first-degree relative.
2. DNA-based evidence of mutation in the LDLR, APOB or PCSK9 gene.
Probable FH
1. Severely elevated cholesterol* and family history of myocardial infarction before age 50 years in a second-
degree relative or before age 60 years in a first-degree relative;
OR
2. Severely elevated cholesterol* and family history of raised total cholesterol concentration >7.5 mmol/L in a 
first or second-degree relative.
LDLR = low-density lipoprotein receptor; APOB = apolipoprotein B; PCSK9 = proprotein convertase subtilisin/kexin type 9.
*Adult: TC>7.5 mmol/L or LDL-C >4.9 mmol/L; Child (<16 years): TC >6.7 mmol/L or LDL-C >4.0 mmol/L
Table 3. Common secondary causes of dyslipidaemia 
Raised LDL-C Mixed dyslipidaemia Raised TG
• Diabetes mellitus
• Hypothyroidism
• Liver disease (biliary obstruction)














• IV lipid emulsion
• Protease inhibitors
• Diabetes mellitus
• Weight gain and obesity
• Pregnancy







• IV lipid emulsion
• Protease inhibitors
LDL-C = low-density lipoprotein cholesterol; TG = triglycerides; IV = intravenous.
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risk tables may under- or overestimate the risk in SA black, coloured 
and Indian patients. The Framingham CVD risk tables for men and 
women and an algorithm for management and cholesterol goals have 
been incorporated into these recommendations (Appendix 1).
Various downloadable mobile device applications (‘apps’) for risk 
scoring are available and clinicians are encouraged to make use of 
these to facilitate management decisions at point of care or at the 
bedside. An app that is appropriate to this guideline is available via 
the App store under ‘SADyslipidaemia’. Other helpful app-based 
scoring systems are listed in Appendix 2.
7. Goals of therapy
Although TC and HDL-C are used to estimate CV risk, LDL-C is the 
target of therapy. Target LDL-C values for patients at different levels 
of Framingham CV risk are listed in Table 4. For those at low or 
moderate risk, target LDL-C is <3 mmol/L. The target for individuals 
at high or very high risk is dependent on the baseline LDL-C level.
For those at high risk, the target LDL-C is <2.5 mmol/L and if 
baseline LDL-C is between 2.5 and 5.2 mmol/L then at least a 50% 
reduction in LDL-C must also be achieved. For those at very high 
risk, the target LDL-C is <1.8 mmol/L and if the baseline LDL-C is 
between 1.8 and 3.5 mmol/L, then at least, a 50% reduction in LDL-C 
must also be achieved.
Notwithstanding these recommendations, clinical studies indicate 
that there is no apparent LDL-C threshold below which CV benefit 
does not continue to accrue or which may be detrimental to health. 
Consequently, particularly for patients at high risk of CV events, 
the primary goal should be to achieve the largest LDL-C reduction 
possible.[26-29]
At their maximum doses, different lipid-lowering therapies do 
differ in their capacity to reduce LDL-C, but CV benefit is dependent 
on the extent to which LDL-C is lowered and not on the type of 
therapy used.[30] 
Meta-analyses of statin trials have shown that every 1 mmol/L 
reduction in LDL-C is associated with a:[31]
• 10% reduction in all-cause mortality
• 20% reduction in deaths due to CHD
• 24% reduction in major coronary events
• 15% reduction in stroke.
This relative effect of lipid-lowering therapy is similar in all patient 
subgroups (with or without vascular disease, male and female, high 
and low CV risk) and becomes significant after 1 year, increasing 
progressively thereafter.[26,27,31-34] The number needed to treat (NNT) 
to prevent adverse CV events is lowest in patients with the highest 
risk at baseline.
There are no target values for HDL-C or TG. However, HDL-C 
>1.0 mmol/L in men and >1.2 in women, and TG <1.7 mmol/L 
indicate lower risk. Higher TG levels should prompt investigation for 
other risk factors.
Table 4. Low-density lipoprotein (LDL-C) treatment targets
Total Framingham CVD risk (%) ESC/EAS risk classification ESC/EAS LDL-C target
<3 Low risk <3.0 mmol/L
3 - 15 Moderate risk <3.0 mmol/L
15 - 30 High risk
<2.5 mmol/L
and a reduction of at least 50% if the baseline* is between 
2.5 and 5.2 mmol/L.
>30 Very high risk
<1.8 mmol/L
and a reduction of at least 50% if the baseline* is between 
1.8 and 3.5 mmol/L.
CVD = cardiovascular disease; ESC =European Society of Cardiology; EAS European Atherosclerosis Society (EAS).
*Baseline LDL-C refers to the level in a subject who is not taking any lipid-lowering therapy.
Table 5. Subjects considered to be at very high or high risk of CV events who DO NOT require Framingham risk scoring
Very high risk
• Established atherosclerotic disease,* i.e.
• Coronary artery disease
• Cerebrovascular disease
• Peripheral arterial disease
• Type 2 diabetes plus one or more other risk factors (smoking, hypertension, dyslipidaemia) or age >40 years
• Type 1 diabetes with micro-albuminuria or proteinuria
• Genetic dyslipidaemia, e.g. FH, dysbetalipoproteinaemia, individuals with TC >7.5 mmol/L and/or LDL-C >5 mmol/L
• Severe CKD (GFR <30 mL/min/1.73 m2) 
• Asymptomatic individuals with arterial plaque demonstrated on imaging modalities
High risk
• Markedly elevated BP (systolic BP ≥180 mmHg and/or diastolic BP ≥110 mmHg)
• Uncomplicated type 1 diabetes and type 2 diabetes aged <40 years without other risk factors
• Chronic kidney disease (GFR 30 - 59 mL/min/1.73 m2) 
CV = cardiovascular; FH = familial hypercholesterolaemia, TC = total cholesterol; LDL-C = low-density lipoprotein cholesterol; CKD = chronic kidney 
disease; GFR = glomerular filtration rate; BP = blood pressure.
*Documented cardiovascular disease on imaging is what has been shown to be strongly predisposed to clinical events, such as plaque on coronary 
angiography or carotid ultrasound.[5]
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8. Management of dyslipidaemia
Because the total cardiovascular risk in an individual is the product 
of a number of risk factors, the treatment of dyslipidaemia must 
always be seen within the broader framework of CVD prevention. 
Table 6 sets out the recommended appropriate intervention strategies 
according to the percentage risk calculated from the Framingham 
risk score and LDL-C values.
8.1 Lifestyle modification
It should be emphasised that the cornerstone of any programme to reduce 
cardiovascular risk is TLC. Specific lifestyle changes that have the most 
pronounced benefit on lipids are reduction of dietary trans and saturated 
fats, increase in dietary fibre, reduction of excessive body weight, reduced 
alcohol intake and increase in habitual physical activity.[5]
Nutrition may also need to be modified for people with unusual or 
specific disorders (e.g. hypertriglyceridaemia). Referral to a dietitian 
and fitness professional is encouraged. The lifestyle and dietary advice 
that is relevant to the South African population is listed in Appendix 3.
8.1.1 Nutrition
Dietary patterns that are most strongly associated with proven 
reduction in long-term CV risk are the Dietary Approaches to 
Stop Hypertension (DASH) and Mediterranean diets.[35-43] They 
are characterised by increased consumption of vegetables, fruits 
and wholegrain products; frequent intake of legumes, nuts, fish, 
poultry and low-fat dairy products, and limited intake of red meat, 
sweets, added sugar and sugar-sweetened drinks. Dietary fat is 
predominantly provided by non-tropical vegetable oil rather than 
animal sources. Incorporating either of these eating patterns into a 
lifestyle is achievable and sustainable. The South African food-based 
dietary guidelines are in line with these recommendations.[44] 
Other specific diets may be tailored to achieve weight loss 
(especially in the short-term) or to address particular health 
concerns, such as dyslipidaemia, celiac disease or diabetes. In short 
term studies (up to 2 years), weight loss was comparable regardless 
of the macronutrient composition of the diet (e.g., low-carbohydrate 
v. low-fat diet), and was not predicted by polymorphisms in genes 
associated with fat or carbohydrate metabolism (low-fat responsive 
and low-carbohydrate responsive genotypes), or insulin concentration 
following a glucose challenge.[45-48] In contrast, large, long-term (6 to 
>25 years) observational studies indicate that habitual adherence 
to a diet low in carbohydrate and high in animal-based sources of 
protein and fat is associated with increased all-cause mortality rates, 
including deaths from CVD and cancer.[49-54] 
The overall nutritional content of the diet is important. Low-
carbohydrate diets tend to be associated with a reduced intake of fibre 
(fruits and vegetables) and increased intake of protein from animal 
sources, cholesterol and saturated fat.[54] Conversely, in people following 
a low-saturated-fat diet, the health benefits may be offset by higher 
consumption of refined carbohydrates.[55] Any diet that concentrates on 
individual or limited food groups, or an imbalance of food groups, will 
not be sustainable and is likely to be nutritionally deficient. 
Considering the multitude and diversity of dietary approaches 
recommended in the media, and the inconsistency of nutritional 
messages from one ‘expert’ to the next, it is no wonder that 
both consumers and health professionals are confused from time 
to time as to what foods are really healthy! Nevertheless, there 
is convincing evidence that the basic principles guiding dietary 
choices that are conducive to maintaining a healthy body weight 
and optimising cardiovascular and life-long health are relatively 
simple. A healthy diet is one of moderation that is nutrient dense, 
and which emphasises adequate intake of fruits, vegetables, whole 
grains, legumes and nuts, and limits consumption of refined grains, 
processed foods, added sugar and sodium, and saturated and trans 
fats. In order to be sustainable, a diet should be culturally acceptable 
and above all, enjoyable.[44,56-58] 
Examples of foods that can improve overall lipoprotein profile or 
which should be consumed sparingly are listed in Appendix 4.
8.1.2 Dietary fats
Fats is an all-encompassing term that includes cholesterol and TG, 
both consumed in food. Dietary TG may be in the form of a solid or 
a liquid (oil). Fats are important in that they confer texture and taste 
to food and promote satiety. However, preference should be given 
to consumption of polyunsaturated fats rather than saturated fats to 
improve the quality of fat in the diet.[59] 
8.1.2.1 Unsaturated fats 
Unsaturated fats are classified as mono- or polyunsaturated. Dietary 
polyunsaturated fatty acids are key as they provide the two essential 
fatty acids that the human body cannot manufacture. These are derived 
mainly from plant and vegetable oils and are the omega-6 linoleic 
acid (from sunflower and soybean oils) and the omega-3 alpha-
linolenic acid (from green leafy vegetables, canola oil and flaxseeds). 
Alpha-linolenic acid is also the precursor of eicosapentaenoic acid 
(EPA) and docosahexaenoic acid (DHA), but these two fatty acids 
are mainly provided by marine sources. Replacing saturated fat with 
polyunsaturated fatty acids (PUFAs) PUFAs from vegetable oil has 
Table 6. Recommended intervention strategies as a function of Framingham total CVD risk score and LDL-C levels[5]* 
Total CVD risk score†
LDL-C levels (mmol/L)
<1.8 1.8 - <2.5 2.5 - 4.9 >4.9
<3%
Low risk
No lipid intervention No lipid intervention Lifestyle intervention
Lifestyle intervention, 
consider drug if uncontrolled
3 - 15%
Moderate risk
Lifestyle intervention Lifestyle intervention
Lifestyle intervention, consider 
drug if uncontrolled
Lifestyle intervention, 







Lifestyle intervention and 
immediate drug intervention







and immediate drug 
intervention
Lifestyle intervention and 
immediate drug intervention
Lifestyle intervention and 
immediate drug intervention
CVD = cardiovascular disease; LDL-C = low-density lipoprotein cholesterol.
*Adapted from Catapano et al. (Table 5). 
†Based on the Framingham CVD risk tables (Appendix 1).
‡In patients with myocardial infarction, statin therapy should be considered regardless of LDL-C levels.
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been shown to reduce LDL-C and CV risk, and may cause regression 
of atherosclerosis.[55]
Observational evidence indicates that twice-weekly consumption 
of fish providing omega-3 fatty acids (EPA and DHA) may reduce 
the risk of CV death and stroke.[5] CVD reduction is greater with 
consumption of polyunsaturated than with monounsaturated fats, 
but both are preferable to saturated fats.[55]
8.1.2.2 Saturated fats 
Saturated fats are predominantly solid and include both animal and 
vegetable solid fats (e.g., visible fat on meat and chicken, lard and 
dairy cream; coconut, palm and palm kernel) and food products 
that have vegetable fats as an ingredient (e.g., non-dairy creamer). 
Because saturated fat is an integral component of fats and oils in 
varying quantities, most dietary products contain some saturated fat. 
Even sunflower oil and olive oil contain saturated fat, but in smaller 
quantities than in the foods mentioned above. Therefore, a diet that 
is high in fat, or which is associated with an increase in total fat 
consumption, will also be associated with higher intake of saturated fat. 
Saturated fatty acids are the dietary fats with the greatest impact on 
LDL-C (0.02 - 0.04 mmol/L LDL-C increase for every additional 1% 
energy coming from saturated fat).[5] 
Randomised controlled trials have shown that reducing intake of 
dietary saturated fat and replacing it with polyunsaturated vegetable oil 
can reduce CVD by ~30%, similar to that achieved by statin treatment.[55]
8.1.2.3 Trans unsaturated fatty acids 
Trans unsaturated fatty acids are monounsaturated or 
polyunsaturated fatty acids containing at least one double bond in 
the trans configuration. They occur naturally in the meat and milk 
of ruminant animals (e.g., cattle, sheep) and are also produced 
commercially for use in partially hydrogenated vegetable oils. These 
industrial trans fatty acids are inexpensive, have a long shelf-life 
and are able to withstand repeated heating. Consequently, they are 
widely used in production of processed foods, including margarines, 
baked goods and commercial deep-fried foods. Clinical trials 
have consistently demonstrated adverse health effects associated 
with industrial trans fatty acids, which include raising LDL-C, 
apolipoprotein B, TG and lipoprotein(a) (Lp(a)), as well as lowering 
HDL-C and apolipoprotein A1 and increasing the risk of CHD.[55,59] 
The use of trans fats in foodstuffs is regulated in SA.[60]
8.1.2.4 Dietary cholesterol
Animal products provide cholesterol similarly in all muscle tissue 
and more so in organ meat and eggs. However, the effects of dietary 
cholesterol on blood cholesterol vary markedly from person to person 
and dietary cholesterol has less of an impact on blood cholesterol 
than saturated fats, which are consistently adverse. It should be noted 
that because saturated fat increases both LDL-C and HDL-C levels, 
the TC/HDL-C ratio will not be greatly affected despite an adverse 
change in LDL-C.
It should be noted that the dietary recommendations provided 
here aim to provide general guidance on a sustainable, healthy intake 
of fats, assuming maintenance of an ideal body weight. For detailed 
information about dietary fats and nutrition in general, readers 
are referred to the South African Food-Based Dietary Guidelines 
available at: http://www.adsa.org.za/Portals/14/Documents/
FoodBasedDietaryGuidelinesforSouthAfrica.pdf.[44] Readers should 
also refer to the appropriate treatment guidelines when providing 
dietary guidance to patients with specific nutritional needs (e.g., 
diabetes mellitus, CKD, weight loss). 
8.1.2.5 Supplements
Epidemiological and interventional studies support the role of 
healthy dietary choices to help reduce the risk of cardiovascular 
events. However, it is important to emphasise that, as far as possible, 
nutrient intake should come from foods and there is insufficient 
evidence to recommend the use of dietary supplements in patients 
with dyslipidaemia. While some dietary supplements have been 
shown to influence plasma lipids, there are no outcome data that 
show reduction in CV events. Conversely, there is evidence that 
some supplements may be harmful to health and may interact 
with prescription medicines.[61,62] Consumers should be aware of 
unsubstantiated advertising claims relating to long-term health 
benefits.
Although there are no known risks associated with its use, the 
routine use of coenzyme Q10 to reduce statin-related myalgia or 
myopathy is not supported by systematic reviews.[63,64]
8.1.3 Tobacco smoking and vaping
Tobacco smoking and passive smoking are harmful to cardiovascular 
health in both adults and children.[65-66] All current smokers should be 
advised to stop smoking. 
Although electronic cigarettes (e-cigarettes, vaping) are considered 
to be less harmful than cigarettes and may be a less unhealthy 
replacement for traditional smoking, especially in those who are 
trying to cut down or quit smoking, the long-term health effects of 
vaping are unknown. Non-smokers should be encouraged to remain 
so and young people in particular should be advised against starting 
smoking.[67,68]
8.2 Statin therapy
8.2.1 Benefits of statin therapy
A wealth of evidence from both observational and large randomised 
controlled clinical trials (RCTs) support the use of statins in a wide 
variety of patients with hypercholesterolaemia. The absolute benefit 
of treatment depends on the individual’s absolute risk of CVD and 
the absolute reduction of LDL-C achieved, but evidence from RCTs 
shows that for every year of statin therapy after the first year, the 
risk of major coronary events (i.e. coronary deaths or myocardial 
infarctions and coronary revascularisation procedures) is reduced by 
approximately one-quarter for each 1 mmol/L reduction in LDL-C. 
Not only do the benefits accrue with ongoing statin use, but they are 
also persistent in the long term.[31,34]
8.2.2 Adverse effects of statins
Statins are remarkably safe drugs and the benefits of cardiovascular 
protection far outweigh the risks of therapy. However, patients should 
be encouraged to make and sustain healthy lifestyle choices and the 
lowest dose of statin necessary to achieve LDL-C target should be 
used (and a 50% reduction in LDL-C if baseline LDL-C is between 1.8 
and 3.5 mmol/L in individuals at very high risk or between 2.5 and 
5.2 mmol/L in those at high risk; see Table 5).
The only noteworthy serious adverse events associated with 
long-term statin therapy are myopathy, new onset diabetes and 
haemorrhagic stroke. However, these adverse effects are relatively 
uncommon with incidences of 5, 50 - 100 and 5 - 10 per 10 
000 patients treated for 5 years, respectively. Although in routine 
clinical practice symptomatic adverse events (e.g., myalgia, or muscle 
weakness) are reported to occur in up to 50 - 100 per 10 000 patients 
treated for 5 years, placebo-controlled RCTs indicate that almost 
all of these incidences are incorrectly attributed to the statin and 
are more likely to be due to another cause.[34] It is not necessary 
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to test muscle enzymes (creatine kinase (CK)) and liver functions 
(alanine aminotransferase (ALT)) in all patients before initiating 
treatment with a statin. Consider testing CK at baseline in patients 
who report unexplained muscle pain or report statin-associated 
muscle symptoms in the past. ALT should be tested in patients with a 
past history of hepatic abnormalities or when there is a high clinical 
suspicion of liver disease (e.g., non-alcoholic fatty liver disease in 
obese patients, high alcohol intake). 
An algorithm for the management of muscle symptoms in statin-
treated patients is shown in Appendix 5. 
Statins have been associated with a small increased risk of 
dysglycaemia, new onset diabetes mellitus and a minor, clinically 
irrelevant elevation of glycated haemoglobin (HbA1c). The number 
needed to treat (NNT) to cause one new case of diabetes mellitus is 
estimated at 255 over 4 years, although the risk may be greater with 
high doses of more potent statins, in the elderly and in individuals with 
other risk factors for diabetes, such as overweight or insulin resistance. 
Overall, in high-risk individuals, the absolute reduction in CVD events 
with statins outweighs the possible risk of diabetes.[6]
8.2.3 High-dose simvastatin treatment
In comparison with maximum doses of atorvastatin and rosuvastatin, 
high doses of simvastatin carry greater risk of both myopathy 
and clinically significant interactions with other drugs. Therefore, 
Table 7. Practical guide to initiating statins depending on baseline LDL-C and target LDL-C values*† 
Starting LDL-C 
(mmol/L)








Rosuvastatin 40 mg 
Atorvastatin 80 mg
>60†
Rosuvastatin 40 mg 
Atorvastatin 80 mg
>55
Rosuvastatin 40 mg 
Atorvastatin 80 mg
5.2 - 6.2 65 - 70‡
Rosuvastatin 40 mg 
Atorvastatin 80 mg
50 - 60
Rosuvastatin 20 mg 
Atorvastatin 40 mg
40 - 55
Rosuvastatin 10 mg 
Atorvastatin 20 mg
4.4 - 5.2 60 - 65‡
Rosuvastatin 40 mg 
Atorvastatin 80 mg
40 - 50






Simvastatin 20 mg 
Lovastatin 40 mg
Fluvastatin 80 mg
3.9 - 4.4 55 - 60
Rosuvastatin 40 mg
Atorvastatin 80 mg 35 - 40
Rosuvastatin 5 mg 
Atorvastatin 10 mg
Simvastatin 20 mg 









3.4 - 3.9 45 - 55
Rosuvastatin 10 mg
Atorvastatin 40 mg 25 - 35
Rosuvastatin 5 mg
Atorvastatin 10 mg




10 - 25 Any statin at lowest dose
2.9 - 3.4 35 - 45
Rosuvastatin 5 mg 
Atorvastatin 10 mg
Simvastatin 20 mg 
Lovastatin 40 mg 
Fluvastatin 80 mg
10 - 25
Any statin at lowest 
dose
<10 Any statin at lowest dose
2.3 - 2.9 22 - 35
Rosuvastatin 5 mg
Atorvastatin 10 mg





Any statin at lowest 
dose
-
1.8 - 2.3 <22
Rosuvastatin 5 mg
Atorvastatin 10 mg





LDL-C = low-density lipoprotein cholesterol.
*Adapted from 2016 ESC/EAS guidelines for the management of dyslipidaemias. Eur Heart J 2016[5] and Weng T-C, et al., J Clin Pharm Ther 2010;35:139-
151.[70]
†Based on weighted average of pooled analysis at starting dose. Dose should be titrated according to response. 
‡Maximum LDL-C reduction achievable with high-dose statin monotherapy is 50 - 60%. To achieve a reduction in LDL-C of >60%, another cholesterol-
lowering agent in addition to statin therapy may be required. Addition of ezetimibe can increase lipid lowering by ~20% and addition of a PCSK9 inhibitor 
can increase lipid lowering by ~50 - 70%.
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it is recommended that patients who do not reach their LDL-C 
goal with 40 mg simvastatin, or who need to start taking another 
drug that may interact with simvastatin, should be switched to an 
appropriate alternative statin, such as rosuvastatin or atorvastatin. If 
it is necessary to co-prescribe simvastatin with other drugs, do not 
exceed 10 mg simvastatin with amiodarone, verapamil or diltiazem, 
and do not exceed 20 mg simvastatin with amlodipine. Simvastatin 
is contraindicated with azole antifungals, macrolide antibiotics, HIV 
protease inhibitors, gemfibrozil, cyclosporine and danazol.[69]
8.2.4 Scheme for introducing statin treatment 
• First evaluate the Framingham risk in primary prevention, or 
identify the patient as deserving of secondary prevention.
• Involve the patient in CV risk management decisions.
• Identify the appropriate LDL-C target.
• Calculate percentage reduction in LDL-C required to reach target.
• Choose the statin (and dose) able to achieve the desired reduction 
(Table 7). 
• Choice of statin should also be appropriate considering comorbidities, 
concomitant drug therapy, tolerability and affordability.
• The dose of statin should be up-titrated to achieve the LDL-C 
target (and a 50% reduction in LDL-C if baseline LDL-C is between 
1.8 and 3.5 mmol/L in individuals at very high risk or between 
2.5 and 5.2 mmol/L in those at high risk (Table 5), unless adverse 
effects prohibit further dose modification).
• If target is not reached at maximal dose, consider a more potent 
statin or add a lipid-lowering drug from another class.
8.3 Ezetimibe
In the IMPROVE-IT study, the cholesterol absorption inhibitor 
ezetimibe in combination with a statin was shown to incrementally 
reduce LDL-C and to reduce the incidence of myocardial 
infarction (MI), coronary revascularisation, ischaemic stroke and 
cardiovascular mortality in patients who had been hospitalised for 
acute coronary syndrome.[28] Reducing LDL-C to levels as low as 
1.4 mmol/L was safe and well tolerated and the reduction in events 
was consistent with the magnitude of LDL-C achieved and those 
reported in other studies.[31] 
Ezetimibe is recommended:
• as second-line treatment in combination with a statin when the 
LDL-C target is not achieved with the highest tolerated statin 
dose
• when there is intolerance to statins
• when there is a contraindication to a statin.
8.4 PCSK9 inhibitors
The proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors 
are a new class of lipid-lowering drugs. Under normal conditions, 
PCSK9 binds to LDL receptors and prevents them from recycling to 
the cell surface after internalisation. Inhibition of PCSK9 therefore 
facilitates recycling of the receptor leading to increased expression 
of LDL receptors on the surface of hepatocytes, which significantly 
enhances clearance of circulating LDL.[71] In a range of patients, 
including those with diabetes or pre-existing atherosclerotic disease, 
a PCSK9 inhibitor administered subcutaneously once every 2 or 4 
weeks reduced LDL-C levels by ~50 - 70%. There was a consistent 
relationship between lower achieved LDL-C and lower risk of 
CV events that was significant within the first year of treatment. 
Treatment with the PCSK9 inhibitor was safe and well tolerated, 
including patients reaching LDL-C levels <0.2 mmol/L.[29,72-78] To 
date, two PCSK9 inhibitors, evolocumab and alirocumab, have been 
licensed by EU and US medicines regulatory authorities. 
Patients for whom a PCSK9 inhibitor might be considered are 
listed in Table 8. Groups 1 and 2 are at the highest risk of CVD events 
and would therefore gain the most benefit from drug treatment, and 
therefore should be prioritised where cost prohibits wider use. 
We would recommend that a national registry be established for 
such high-risk patients, including those with a formal diagnosis of 
FH, and that use of the PCSK9 inhibitors be restricted to patients 
enrolled in this national database. 
8.5 Management of hypertriglyceridaemia
Pharmacotherapy for management of hypertriglyceridaemia 
should be considered in patients at high and very high risk of 
CVD and/or pancreatitis and with TG >2.3 mmol/L. Unless 
hypertriglyceridaemia exceeds 10 mmol/L, the preferred treatment 
is a statin. There is uncertainty as to the best management approach 
when TG remain >2.3 mmol/L despite optimal statin therapy, but, 
based on a retrospective analysis of the ACCORD study, addition 
of fenofibrate may be considered.[80,81] Unless there is a specific 
indication to justify their use, other combination therapies are 
discouraged.
Although n-3 fatty acids reduce TGs, their effects on other 
lipoproteins are negligible and, at present, there is insufficient 
evidence to recommend them for routine management of 
hypertriglyceridaemia. 
Severe hypertriglyceridaemia (TG >10 mmol/L) is associated 
with a significant risk of pancreatitis and preventative strategies 
should be implemented as a matter of urgency. Patients may require 
admission to hospital with careful monitoring of TG levels and, 
where appropriate, investigation for a secondary cause. Dietary 
calories and fat content (10 - 15% recommended) should be 
restricted, alcohol is forbidden, and diabetes, a frequent precipitant, 
should be treated aggressively (start or intensify insulin) if it is 
present. Fibrate therapy (fenofibrate) should be initiated either as 
monotherapy or in combination with n-3 fatty acids (2 - 4 g/day) 
or nicotinic acid. Where it is necessary, plasmapheresis may be 
considered, and causes rapid reduction in TG levels. 
8.6 Pharmacotherapy affecting high-density lipoprotein 
cholesterol
While low levels of HDL-C are predictive of CVD risk, 
pharmacotherapy aimed exclusively at modifying HDL-C has not 
been shown to be of any benefit in reducing atherosclerotic events. 
Statins and fibrates increase HDL-C levels to a similar degree, but 
the efficacy of fibrates may be attenuated in people with type 2 
diabetes. 
8.7 Bile acid sequestrants
Bile acid sequestrants and nicotinic acid have cholesterol-lowering 
properties. They may occasionally be useful alone or in combination 
with statin therapy. However, their side-effects limit wider application 
and their use is discouraged. Bile acid sequestrants are not readily 
available in SA.
9. Approach to primary prevention
Risk factor scoring has its limits and in primary prevention may over- or 
underestimate actual risk. Furthermore, there are currently insufficient 
numbers of primary prevention trials to make strong recommendations 
about the use of statins in populations with intermediate Framingham 
risk scores.[82] Under these circumstances, where a patient is considered 
to be at moderate risk and where there is uncertainty about whether to 
initiate drug therapy, the use of novel biomarkers of CVD (e.g. high-
sensitivity C-reactive protein (hsCRP)) and imaging technologies (e.g. 
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coronary calcium scoring, carotid intima-media thickness) might be 
helpful to refine risk assessment.[5] However, it should be borne in mind 
that their role is in supporting a decision to treat rather than to justify 
not treating. Modalities include the following:
9.1 Lipoprotein(a)
Recent studies have identified elevated lipoprotein(a) (Lp(a)) as a 
causal and independent risk factor for CVD.[83] Lp(a) concentration 
is genetically determined and is stable over time. Risk is considered 
important when Lp(a) is >50 mg/dl (>125 nmol/L). Screening is not 
recommended for the general population, but may be considered for 
reclassification of subjects falling on a borderline between moderate 
and high risk. Lp(a) screening can also be considered for selected 
individuals at high CVD risk, including those with premature CVD, 
FH, a family history of premature CVD and/or elevated Lp(a), 
recurrent CVD despite optimal lipid-lowering treatment, and risk 
≥15% on the 10-year Framingham risk tables. 
9.2 Lipoprotein particle size
The metabolic syndrome is associated with small dense LDL that, 
in conjunction with mild hypertriglyceridaemia and low HDL-C 
levels, indicates higher CVD risk (Table 9).[84] Although subclasses 
of LDL may contribute differently to risk estimation and may be 
of benefit in risk assessment at the border of risk level for decision 
of drug prescription, there are no studies that have prospectively 
evaluated this approach. Measurement of LDL particle size is not 
part of the diagnostic criteria for the metabolic syndrome and is 
therefore not recommended, but may help to identify patients with 
dysbetalipoproteinaemia or lipoprotein X.
9.3 High-sensitivity C-reactive protein 
hsCRP is a nonspecific inflammatory marker that may be elevated in 
many infectious or non-infectious inflammatory conditions. In the 
absence of other causes, elevated hsCRP may signify an increased risk 
of CVD. Ideally, hsCRP should be <1 mg/L, whereas hsCRP >3 mg/L 
signifies high risk of CVD and hsCRP >10 mg/L is likely to be due 
to another inflammatory cause. In selected individuals where there is 
uncertainty regarding initiation of statin treatment, hsCRP >2 mg/L 
supports revising the risk assessment upward.[85] hsCRP is included in 
the Reynolds risk score assessment (Appendix 2). 
9.4. Coronary artery calcium score 
Coronary artery calcium (CAC) indicates atherosclerosis and its 
extent relates to total plaque burden. It is considered to be the most 
robust predictor of CV events in asymptomatic patients, allowing 
improved accuracy and personalisation of CV risk, especially among 
those with intermediate risk based on risk factor scoring.[86] 
CAC is most commonly quantified by the Agatston method 
(Table 10). A CAC score of 0 is consistently associated with low 
(~ 1%) 10-year CVD risk, regardless of risk factor status. Conversely, 
a CAC score >400 is considered justification for modification of an 
intermediate CVD risk factor score.[5,86]
CAC does not predict degree of atherosclerotic stenosis or soft 
plaque and is of no value in symptomatic patients, or those who are 
already on treatment. Serial CAC scans do not add significantly to 
risk prediction and are not recommended. However, in a patient with 
an initial CAC score of 0 and who is not on statin therapy, a repeat 
scan may be considered after 5 years, when a second CAC score of 0 
is highly predictive and reassuring of very low CVD risk.[87]
9.5 Carotid ultrasound
There is a correlation between the severity of atherosclerosis in 
one arterial territory and the involvement of other arteries. Carotid 
ultrasound is commonly used to establish the presence of atherosclerosis 
Table 8. Patients who may be appropriate for a PCSK9 inhibitor[79]
1. Patients with atherosclerotic CVD (CAD, symptomatic PAD, 
ischaemic stroke) at very high risk who have substantially elevated 
LDL-C levels despite maximally tolerated statin with or without 
ezetimibe therapy, and thus are considered at particularly high risk 
of an adverse CV outcome.
A) LDL-C >3.6 mmol/L
B) LDL-C >2.6 mmol/L and with additional indices of risk severity, 
including:
• FH
• diabetes mellitus with target organ damage or a major risk factor (e.g., 
marked hypertension)
• severe and/or extensive atherosclerotic CVD (e.g., severe polyvascular 
disease or extensive coronary disease*)
2. FH patients without clinically diagnosed ASCVD, at high or very 
high cardiovascular risk, and with substantially elevated LDL-C 
levels despite maximally tolerated statin plus ezetimibe therapy.
A) No additional indices of risk severity and LDL-C >4.5 mmol/L
B) LDL-C >3.6 mmol/L with additional indices of risk severity:
• diabetes mellitus with target organ damage or a major risk factor (e.g., 
marked hypertension)
• Lp(a) >50 mg/dL (>125 nmol/L)
• major risk factors: smoking, marked hypertension
• premature CVD in first-degree relative
• imaging indicators of extensive atherosclerosis (e.g., carotid artery 
ultrasound; CTA*)
3. Patients with atherosclerotic CVD and at very high risk who do 
not tolerate appropriate doses of at least three statins and who have 
elevated LDL-C levels despite alternative lipid-lowering therapies, 
such as ezetimibe.
PCSK9 = proprotein convertase subtilisin/kexin type 9; CVD = cardiovascular disease; CAD = coronary artery disease; PAD = peripheral artery 
disease; LDL-C = low-density lipoprotein cholesterol; FH = familial hypercholesterolaemia; ASCVD = atherosclerotic cardiovascular disease; Lp(a) = 
lipoprotein(a); CTA = computed tomography angiography.
*Markers of high risk with coronary computed tomography angiography (CTA): 
1. Global high-risk markers: left main disease, proximal left anterior descending disease, 3-vessel coronary disease
2. Focal high-risk markers: stenosis severity >50% luminal obstruction, lesion composition: mixed or non-calcified (reflecting earlier, unstable 
atherosclerosis).
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and may be used to measure both intima-medial thickness (cIMT) and 
the presence and characteristics of atherosclerotic plaques. cIMT is a 
measure of both early atherosclerosis and smooth muscle hypertrophy/
hyperplasia and a value >0.9 mm is considered abnormal. However, 
the risk of stroke or cardiac events associated with cIMT is non-linear, 
with risk increasing more rapidly at lower cIMTs and clinical studies 
have been unable to demonstrate any additional benefit of cIMT over 
Framingham risk analysis in predicting CVD risk. Therefore, routine 
measurement of cIMT is not recommended for risk assessment for a 
first atherosclerotic vascular event.
In contrast, the presence of carotid plaque is a stronger and more 
accurate predictor of CVD risk. Plaque is defined as a focal structure 
of the inner vessel wall at least ≥0.5 mm (or ≥50% thickening of 
IMT), or any cIMT measurement ≥1.5 mm that protrudes into the 
lumen. CVD risk increases incrementally with increasing number 
of plaques, and with plaque volume, area and thickness. Therefore, 
in selected individuals, carotid artery plaque assessment may be 
considered a risk modifier, where identification of carotid plaque 
places the individual in the high or very high risk category.[6,88,89]
10. Special patient populations
10.1 Screening and statin therapy in children younger 
than 16 years of age
Atherosclerosis begins at an early age. In autopsy studies, fatty streaks 
were observable in the aorta of all and in the coronary arteries of 
50% of children aged between 2 and 15 years of age. Approximately 
20% and 8% already had raised fibrous plaque lesions in the aorta 
and coronary arteries, respectively. The severity of atherosclerosis 
increased significantly with increasing number of CV risk factors (body 
mass index, BP, TC, TG, LDL-C, HDL-C, smoking).[90] Accordingly, 
assessment of cardiovascular risk factors and dietary and lifestyle 
intervention for CVD needs to begin at an early age in all children. 
Cholesterol screening is appropriate from 8 years of age in children 
with family history of FH or any other reasons to be considered at high 
CVD risk. Children with CKD are of particular concern. Potentially 
modifiable CV risk factors (especially anaemia) are commonly present 
even in early CKD, and routine screening and timely intervention are 
essential to prevent progression of CVD and early mortality.[91]
When to begin statin therapy for children with FH or who are at 
high risk for CVD is a matter of clinical judgement, but is usually 
appropriate beginning from age 8 years, especially if additional risk 
factors are present. 
10.2 Young adults
CV risk charts may underestimate risk in young people with high 
levels of risk factors, in that a low absolute risk may conceal a very 
high relative risk requiring intensive lifestyle advice. Consequently, 
showing the patient an estimate of their heart (vascular or relative 
risk) age and how that might be reduced by lifestyle change can 
be more effective in motivating lifestyle modification (Appendix 
2). Heart age is independent of the CV endpoint used (i.e. CV 
mortality or total CVD events) and can be used in any population 
regardless of the baseline risk or secular changes in mortality. It is 
the age that corresponds to the age of a person with the same level 
of risk, but with ideal levels of risk factors. In people with CV risk 
factors, heart age can be substantially older than the individual’s 
chronological age.[5,92,93] 
10.3 HIV infection
SA has the largest HIV epidemic worldwide, with approximately 
one-fifth of all infected individuals and 270 000 new infections 
in 2016.[94,95] The phenotype of SA patients with HIV infection is 
different to that in developed countries, where the predominantly 
affected individuals are white males with an average age of 45 years, 
and both HIV infection and antiretroviral treatment, the latter partly 
because of treatment-induced dyslipidaemia, are independently 
associated with an increased risk of CV and cerebrovascular 
events.[95-98] In contrast, in SA, the prevalence of HIV is highest 
among black females aged 30 - 34 years and the rate of new infections 
among women aged 15 - 24 years is more than 4 times that of men of 
the same age.[99] Compared with HIV-negative individuals, significant 
cardiometabolic risk factors are not more common (and may be less 
common) in those with HIV infection and LDL-C levels are usually 
not elevated. Furthermore, although ART may be associated with 
small changes in the lipid profile, severe lipid abnormalities that 
require evaluation and treatment are uncommon.[100-103]
Consequently, considering their age and the low prevalence of 
other CVD risk factors, HIV-positive SA patients are considered 
to be at low risk for CVD events and recommendations for lipid 
management and indications for lipid-lowering drugs in HIV-
positive patients are the same as for HIV-negative individuals. There 
is no validated risk score for HIV-infected black South Africans and 
the Framingham risk tables may be used to aid decision-making. 
Nevertheless, with the exception of those who have severe 
risk factors for CVD (e.g. FH), it is currently unknown how to 
accurately predict risk for individuals with HIV. At least in some 
populations, it is likely that conventional risk tables underestimate 
CV risk.[104] Diet and lifestyle modification should always be advised 
and other CV risk factors must be addressed. 
A full lipogram should be performed before initiating ARV treatment. 
It should be repeated at 3 months after starting treatment with a protease 
inhibitor and thereafter periodically while on therapy. In patients 
with high lipid levels who are already on ARV treatment, switching 
to an alternative ARV and cautious use of a statin or fibrate should be 
SI Units conversion
Cholesterol:
mmol/L = mg/dL × 0.0259
mg/dL = mmol/L × 38.6
Triglyceride:
mmol/L = mg/dL × 0.0113
mg/dL= mmol/L × 88.5
Table 9. Diagnostic criteria for metabolic syndrome[84]
At least 3 of:
1. Elevated waist circumference Men ≥94 cm; women ≥80 cm
2. Elevated TG* ≥1.7 mmol/L or on TG-lowering therapy
3. Reduced HDL-C Men <1.0 mmol/L; women <1.3 mmol/L
4. Elevated BP* Systolic ≥130 and/or diastolic ≥85 mmHg or on antihypertensive therapy
5. Elevated fasting glucose* ≥5.6 mmol/L or on treatment for type 2 diabetes
TG = triglycerides; HDL-C = high-density lipoprotein cholesterol; BP = blood pressure.
*Criterion is regarded as positive if the patient is on treatment directed at this variable.
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considered as necessary. Atorvastatin is the statin of choice in patients 
with HIV. Because of a high risk of drug interactions with ARVs, 
simvastatin is contraindicated and rosuvastatin is not recommended.[105]
Before prescribing, it is recommended that clinicians refer to the 
detailed and interactive information about drug-drug interactions 
between lipid-lowering agents and ARVs available from www.hiv-
druginteractions.org.
10.4 The older adult
CVD is a common cause of both morbidity and mortality among 
adults older than 75 years of age, who are also frequently affected 
by comorbidities, including diabetes mellitus, hypertension, 
hyperlipidaemia and renal dysfunction. Because the absolute risk 
of CV events is very high in this group, even a small relative 
benefit from treatment may be clinically significant. However, 
evidence for lipid-lowering therapy in older individuals, and 
data on choice of statin and dose, are limited. In primary and 
secondary prevention studies, statin therapy was associated with 
a reduction in myocardial infarction and stroke and, in secondary 
prevention studies also with a reduction in cardiovascular mortality.
[106-110] Statins may also reduce cognitive decline.[111-113] The ongoing 
Australian STAREE randomised trial of atorvastatin among adults 
aged ≥70 years is expected to provide further guidance on statin use 
in this population.[114] 
Age, comorbidity and polypharmacy increase the risk of drug-drug 
interactions, side-effects and myopathy, and adherence to medication 
among older patients is often poor. The Framingham risk estimates 
are unreliable in older individuals who will be placed in the high-
risk categories merely based on age and gender. Risk tables for older 
patients have been developed based on the SCORE tables, but these 
have not been validated in a South African population.[115] Therefore, 
clinical judgement should be used to guide treatment decisions and 
avoid side-effects and overmedication. Unless there is a specific 
reason to stop, patients who are already on a statin should continue 
with treatment into older age. Decisions on whether to initiate new 
therapy should be made jointly by the clinician and patient and/or 
their family, with careful consideration of pre-existing dementia, 
disability and dependence on caregivers.
Where statins are prescribed, it would seem prudent to start at a 
low dose with agents that do not commonly interact with other drugs 
and cautiously titrate the statin to achieve target lipid levels.
10.5 Chronic kidney disease
Chronic kidney disease (CKD) is associated with dyslipidaemia, 
which worsens with decreasing GFR. The initial stages of CKD are 
characterised by elevated TG and low HDL-C, whereas TC and 
LDL-C levels are also raised in end-stage renal disease (ESRD), with 
a shift towards an excess of small, dense LDL particles. Individuals 
with a GFR of 30 - 59 mL/min/1.73 m2 or <30 mL/min/1.73 m2 are 
considered to be at high and very high CV risk, respectively, and do 
not require Framingham risk scoring.
The safety of statins in CKD has been well established. A statin 
with or without ezetimibe is recommended for management of 
dyslipidaemia in patients with non-dialysis-dependent CKD. 
Statins should not be initiated in patients with dialysis-dependent 
CKD who are free of atherosclerotic CVD, but where a statin and/
or ezetimibe has been initiated before dialysis, they should be 
continued if dialysis is required. For detailed information about 
lipid management in patients with CKD, readers are referred to the 
KDIGO lipid management guidelines (www.kdigo.org).[116]
11. Secondary prevention
In patients presenting with acute coronary syndrome (ACS), a lipid 
profile should be obtained at the time of admission. Regardless of 
initial LDL-C values, they should be treated with high-intensity lipid-
lowering therapy during their acute care, which should be continued 
after discharge. The dose of lipid-lowering therapy at discharge is 
based on lipid values at admission and the patient’s target values. All 
patients with proven atherosclerotic disease require a target LDL-C 
concentration <1.8 mmol/L and a reduction of at least 50% if the 
baseline LDL-C is between 1.8 and 3.5 mmol/L. Lipids should be 
re-evaluated 4 - 6 weeks after discharge to determine whether target 
levels have been achieved and to evaluate any safety issues. Doses 
should be adjusted accordingly. If the LDL-C target is not reached 
with the highest tolerable statin dose, consider addition of ezetimibe 
and, if necessary and appropriate, a PCSK9 inhibitor. 
Routine short pre-treatment or loading (on the background 
of chronic therapy) with high-dose statins before percutaneous 
coronary intervention (PCI) should be considered in elective PCI 
or in non-ST segment elevation ACS.
12. Residual risk
Partly because of the significant levels of atherosclerotic disease that 
are already present before treatment is initiated, even with the best 
therapy, and despite therapy, there remains a significant residual 
CV event rate.[28,29,72-74] Patients who appear to be at LDL-C goal, yet 
still experience recurrent events must be considered for even lower 
target lipid levels. Research into ameliorating residual risk is ongoing, 
including use of fibrates, omega-3 fatty acids, more intense lowering 
of LDL-C, as well as anti-inflammatory therapies.
Clinicians and their patients must be open to aggressive 
management of all risk factors, including hypertension, plasma 
glucose, healthy eating habits and exercise, as well as meticulous 
adherence to prescribed interventions. Where it is appropriate and 
indicated, antithrombotic therapy should also be considered. 
13. Adherence to therapy
Adherence to prescribed therapy declines over time. It has been 
reported that as many as three-quarters of patients receiving statins 
for primary prevention discontinue their medication within 2 years. 
However, this is not unique to statins and applies to all drugs 
prescribed for CVD. The nonadherence rates are significantly 
greater for medicines prescribed for primary than for secondary 
prevention.[117-119] In contrast, the benefit of statin treatment increases 
incrementally with duration of therapy.[34]
Shared decision making, with frank and open discussion of 
the benefits and risks of both treating and not treating, may 
facilitate decisions on how to proceed and adherence to the chosen 
management strategy.[120]
14. Public health
14.1 Dyslipidaemia is a prescribed minimum benefit
In South Africa, dyslipidaemia is classified under section 29(1) of 
Table 10. Agatston classification of coronary artery 
calcification (CAC)[86]
Total calcium score Classification
0 no CAC
1 - 10  minimal CAC
11 - 100 mild CAC
101 - 400 moderate CAC
>400 severe CAC
>1 000 very severe CAC
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the Medical Schemes Act as a prescribed minimum benefits (PMB) 
condition. Consequently, it is mandatory for medical schemes to 
cover the related costs of diagnosis and treatment. 
14.2 New government treatment recommendations
In contrast to the recommendations of this guideline to treat to a 
predefined, patient-specific target with ongoing monitoring and 
adjustment of therapy, new government recommendations for the 
treatment of dyslipidaemia in South Africa advocate aiming for 
1 mmol/L reduction in LDL-C in all patients regardless of baseline 
LDL-C with a ‘fire and forget’ approach (personal communication, 
Ms K Jamaloodien, National Department of Health, 4 November 
2017). Furthermore, the general recommendation is to prescribe 
10 mg simvastatin, which will not be sufficient to achieve even a 
1 mmol/L reduction of LDL-C in many patients. 
It is the opinion of SA Heart and LASSA that this overly 
generalised approach is clinically irresponsible and will not be cost 
effective, considering the potential costs of managing dyslipidaemia 
appropriately as set out in this guideline versus those related to 
management of patients who survive a cardiovascular event.
15. When to refer
The following patients should be referred for specialist assessment:
• high risk individuals who do not achieve target lipid levels despite 
optimised treatment
• unexplained cutaneous or tendinous lipid deposits (xanthomata) 
• very premature vascular disease
• dyslipidaemia associated with endocrine, metabolic, or neurological 
disorders
• unusually low TC (<2.5 mmol/L) in untreated patients
• unusually high TG (>10 mmol/L), TC (>15 mmol/L), LDL-C (>10 
mmol/L) or HDL-C (>3.0 mmol/L).
16. Conclusions: Implementation of 
the 2018 guidelines
To implement the guidelines, we propose a risk assessment chart 
based on the Framingham risk tables (Appendix 1). The chart is a 
guide to management only and should not replace an individualised 
assessment and treatment plan based on the clinical judgement of 
the doctor. We encourage the reader to read the 2016 European 
guidelines in full, which may be accessed on the ESC website 
www.escardio.org/guidelines. We hope that dissemination of these 
guidelines will go some way towards helping to reduce the burden 
of CVD in SA.
17. Mechanism of guideline 
preparation
In November 2017, a broad-based group of participants from 
the medical and allied health community, medical funders, 
pharmaceutical companies, the Department of Health and the Board 
of Health Funders met in Johannesburg to examine and discuss the 
joint ESC/EAS dyslipidaemia guidelines. The following day, a writing 
committee met to construct the South African Consensus Document, 
which was revised and finalised by the same committee over the 
ensuing 3 months.
In addition to the writing committee, delegates attending the 
Dyslipidaemia Guidelines Meeting Discussion Group were Dr C 
Badenhorst (cardiologist, SASCI), Mrs G Bartlett (Universal Care), 
Ms M Campbell (Discovery Health), Dr J Carapinha (Carapinha & 
Company), Mrs T Celliers (MSD), Mrs C de la Motte (Sandoz), Mr 
D Craythorne (Cipla), Prof. JA Dave (endocrinologist, University 
of Cape Town), Mrs E Fourie (Mediscor), Dr N Habangana 
(MSD), Mrs S Hassan (Medscheme), Ms C Henning (Amgen), 
Ms K Jamaloodien (National Department of Health), Prof. SZ 
Kalula (geriatrician, University of Cape Town), Mr G Kumalo 
(Aspen), Dr E Lai (Sanofi), Dr D Makgai (Pfizer Laboratories), 
Prof. E Makotoko (cardiologist, University of the Free State), 
Dr P Masopha (Sanlam Health Management), Dr N Mohamed 
(endocrinologist, University of the Witwatersrand and SEMDSA), 
Mr K Mungar (Pharma Dynamics), Dr P Naidoo (Sanofi), Dr 
V Ndungane-Tlakula (Amgen), Mr A Nicolson (MSD), Prof. M 
Ntsekhe (cardiologist, University of Cape Town), Dr R Patel (BHF), 
Ms N Ramushi (Abbott Laboratories), Mrs E Schaafsma (SA Heart), 
Dr D Segal (paediatric endocrinologist), Mr F Smuts (Abbott 
Laboratories), Prof. N Wearne (nephrologist, University of Cape 
Town) and Mrs T Woodman (Pharma Dynamics). 
Disclaimer. While every effort has been made to ensure the 
accuracy of the contents at the time of publication, the authors do not 
give any guarantee as to the accuracy of the information contained 
nor accept any liability, with respect to loss, damage, injury or 
expense arising from any errors or omissions in the contents of this 
work. Persons using this guide are reminded prior to administration 
of any drugs to confirm drug doses against the manufacturer’s 
prescribing information or recent medicines formulary and to 
ensure that drug doses administered are clinically appropriate for 
the individual patient receiving them. Reference in the document to 
specific pharmaceutical products does not imply endorsement of any 
of these products.
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Category 1: Individuals considered to be at very high or high risk who do not need scoring
Very high risk
1. Established atherosclerotic disease, i.e.
a. coronary artery disease
b. cerebrovascular disease
c. peripheral arterial disease.
2.  Type 2 diabetes plus one or more other risk factors (smoking, hypertension, dyslipidaemia) or age >40 years.
3.  Type 1 diabetes with micro-albuminuria or proteinuria.
4.  Genetic dyslipidaemia, e.g. familial hypercholesterolemia (FH), dysbetalipoproteinaemia, individuals with total cholesterol (TC) >7.5 
mmol/L and/or low-density lipoprotein cholesterol (LDL-C) >5 mmol/L.
5.  Severe chronic kidney disease (CKD) (glomerular filtration rate (GFR) <30 mL/min/1.73 m2).
6.  Asymptomatic individuals with arterial plaque demonstrated on imaging modalities.
High risk
1.  Markedly elevated blood pressure (BP) (systolic BP ≥180 mmHg and/or diastolic BP ≥110 mmHg).
2.  Uncomplicated type 1 diabetes and type 2 diabetes aged <40 years without other risk factors. 
3. CKD (GFR 30 - 59 mL/min/1.73 m2).  
Goal:† 
• Very high risk: LDL-C <1.8 mmol/L and also a reduction of at least 50% if baseline LDL-C is between 1.8 and 3.5 mmol/L.
• High risk: <2.5 mmol/L and also reduction of at least 50% if baseline LDL-C is between 2.5 and 5.2 mmol/L. 
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Estimate of 10-year risk of CVD for men Estimate of 10-year risk of CVD for women
Age (yrs) Points Age (yrs) Points
30 - 34 0 30 - 34 0
35 - 39 2 35 - 39 2
40 - 44 5 40 - 44 4
45 - 49 6 45 - 49 5
50 - 54 8 50 - 54 7
55 - 59 10 55 - 59 8
60 - 64 11 60 - 64 9
65 - 69 12 65 - 69 10
70 - 74 14 70 - 74 11
75 years or older 15 75 years or older 12
Total cholesterol (mmol/l) Points Total cholesterol (mmol/l) Points
<4.10 0 <4.10 0
4.10 - 5.19 1 4.10 - 5.19 1
5.20 - 6.19 2 5.20 - 6.19 3
6.20 - 7.20 3 6.20 - 7.20 4
>7.20 4 >7.20 5
HDL-cholesterol (mmol/l) Points HDL-cholesterol (mmol/l) Points
≥1.50  -2 ≥1.50  -2
1.30 - 1.49  -1 1.30 - 1.49  -1
1.20 - 1.29 0 1.20 - 1.29 0
0.90 - 1.19 1 0.90 - 1.19 1
<0.90 2 <0.90 2
Systolic BP – untreated (mmHg) Points Systolic BP – untreated (mmHg) Points
<120  -2 <120  -3
120 - 129 0 120 - 129 0
130 - 139 1 130 - 139 1
140 - 159 2 140 - 149 2
≥160 3 150 - 159 4
≥160 5
Systolic BP – on antihypertensive treatment (mmHg) Points Systolic BP – on antihypertensive treatment (mmHg) Points
<120 0 <120  -1
120 - 129 2 120 - 129 2
130 - 139 3 130 - 139 3
140 - 159 4 140 - 149 5
≥160 5 150 - 159 6
≥160 7
Smoker Points Smoker Points
No 0 No 0
Yes 4 Yes 3
Category 2:‡Risk scoring required – use the Framingham Risk tables below.§
Framingham 10-year risk assessment chart for patients without diabetes or severe monogenic disorders (e.g. FH) indicates risk of 
total CVD (coronary heart disease, stroke, peripheral artery disease or heart failure).
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Points total for men Points total for women
Points total 10-year risk (%) Points total 10-year risk (%)
-3 or less <1 -2 or less <1%
-2 1.1 -1 1.0
-1 1.4 0 1.1
0 1.6 1 1.5
1 1.9 2 1.8
2 2.3 3 2.1
3 2.8 4 2.5
4 3.3 5 2.9
5 3.9 6 3.4
6 4.7 7 3.9
7 5.6 8 4.6
8 6.7 9 5.4
9 7.9 10 6.3
10 9.4 11 7.4
11 11.2 12 8.6
12 13.2 13 10.0
13 15.6 14 11.6
14 18.4 15 13.5
15 21.6 16 15.6
16 25.3 17 18.1
17 29.4 18 20.9
18 or more >30 19 24.0
20 27.5
20 or more >30
*Point totals indicate the 10-year risk of cardiovascular disease (coronary, cerebrovascular and peripheral arterial disease, and heart failure).
Low risk                 Moderate risk     High risk   Very high risk
Adapted from Mosca L, et al., Effectiveness-based guidelines for the prevention of cardiovascular disease in women 2011 update: A guideline 
from the American Heart Association. Circulation 2011;123:1243-1262[24] and D’Agostino RB, et al., General cardiovascular risk profile for use 
in primary care: the Framingham Heart Study. Circulation 2008;117:743-753.[25]
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Low risk                 Moderate risk     High risk   Very high risk
Initial CVD risk 3 - <15%
• Institute lifestyle changes
• Consider statin if LDL- C is 
  persistently >3.0 mmol/L
Initial CVD risk 15 - <30%
• Institute lifestyle changes
• Consider statin if LDL-C <2.5 mmol/L
• Start statin immediately if LDL-C >2.5 mmol/L
Initial CVD risk >30%
• Institute lifestyle changes




LDL-C <2.5 mmol/L and also 
a reduction of at least 50% if baseline 
LDL-C is between 2.5 and 5.2 mmol/L
Goal:†
LDL-C <1.8 mmol/L and also a 
reduction of at least 50% if baseline 
LDL-C is between 1.8 and 3.5 mmol/L












Initial CVD risk <3%
• Institute lifestyle changes
• Consider statin if LDL-C is 
  persistently >4.9 mmol/L































†Pharmacological treatment is required if LDL cholesterol remains above these levels despite lifestyle 
modification. At present statins are first-line drugs for lowering LDL cholesterol. 
‡Secondary causes of dyslipidaemia should be excluded before progressing to risk assessment. 
§See limitations of Framingham Risk Assessment Score on this page. 
¶Total cholesterol level is used to assign risk score and may be used for follow-up cholesterol 
measurement in patients on drug therapy, but LDL cholesterol is the target of treatment. 
 
 





Use correct gender table: Score: 
 1. Age 1. ________ 
 2. Total cholesterol¶ 2. ________ 
 3. Non-smoker/smoker 3. ________ 
 4. HDL-C 4. ________ 































HDL-C = high-density lipoprotein cholesterol; BP = blood pressure; CVD = cardiovascular disease; LDL-C = low-density lipoprotein cholesterol. 
*Total cholesterol level is used to assign risk score and may be used for follow-up cholesterol measurement in patients on drug therapy, but LDL-C remains 
the target of treatment. 
†Pharmacological treatment is required if LDL-C remains above these levels despite lifestyle modification. At present, statins are first-line drugs for lowering 
LDL cholesterol.
‡Secondary causes of dyslipidaemia should be excluded before progressing to risk assessment.
§See limitations of Framingham Risk Assessment Score listed below.
§ Limitations of the Framingham Risk Assessment Score Charts
1. Patients who are classified in the very high-risk category do not require further risk scoring for management decisions. Risk will also be underestimated in 
patients who have a markedly elevated single risk factor (e.g. severe hypertension: systolic BP >180 mmHg and/or diastolic BP >110 mmHg), or associated 
target organ damage.
2. Severe hypercholesterolaemia and hypertriglyceridaemia: The Framingham Risk Assessment Chart is only accurate up to TC values of 7.25 mmol/L and 
cannot be used for patients with TC levels above this value. It also does not apply to hypertriglyceridaemia (triglycerides >5 mmol/L).
3. Family history of early atherosclerotic disease is not considered. Clinicians should use their judgement in deciding whether to place a 
patient with an impressive family history in the high-risk category regardless of their Framingham Score, or avoid calculating risk in these patients.
4. Despite these factors being important risk factors for CVD, impaired glucose tolerance, abdominal obesity and lipoprotein(a) (Lp(a)) >50 mg/dL are not 
considered in the risk score.
Management and cholesterol goals according to Framingham risk score
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Appendix 3 
South African Heart Association/LASSA guidelines for lifestyle modification for patients with dyslipidaemia 
1.  Stop smoking and avoid exposure to tobacco products and second-hand smoke.
2.  Increase physical activity to at least 30 minutes per day every day.
3.  Achieve and maintain ideal body weight.
4.  Drink sufficient clean, safe water in preference to carbonated drinks and fruit juices.
5.  Eat a variety of foods with preference for fresh, unprocessed foods.
6. Reduce dietary intake of saturated fats, trans-fats and cholesterol.
7.  Replace dietary saturated fats with unsaturated fats (mono- and polyunsaturated fats).
8.  Avoid tropical oils (e.g., coconut and palm kernel oil).
9.  Increase intake of fibre, especially soluble fibre.
10.  Replace all refined carbohydrate types of foods with foods high in fibre.
12.  People who consume alcohol should do so in moderation. Excessive alcohol consumption should be avoided. Patients with  hypertriglyceridaemia 
should abstain completely.
11.  Avoid foods that are naturally high in sugar, e.g. honey, syrups, fruit juices and foods with added sugar, fructose or corn syrup.
13.  Reduce salt intake from all sources to <5 g salt or <2.4 g sodium, equivalent to 1 teaspoon of salt per day.
14.  For dietary lifestyle intervention, all patients should ideally be referred to a registered dietitian.
Risk scoring applications for mobile devices
Application Parameters required Available from
SA Heart (recommended)* Age, TC, HDL-C, systolic BP, antihypertensive 
treatment use, smoking status
App store: SADyslipidaemia
Framingham risk:
10- and 30-year CVD risk 
Gender, age, systolic BP, blood pressure lowering 





Gender, age, systolic BP, antihypertensive treatment 
use, smoking, diabetes status, BMI or lipids
https://www.framinghamheartstudy.org/risk-functions/
cardiovascular-disease/index.php
ESC relative risk Smoking, BP, TC https://www.escardio.org/Education/Practice-Tools/
CVD-prevention-toolbox/SCORE-Risk-Charts
AHA/ACC Age, sex, race, TC, HDL cholesterol, systolic blood 
pressure, antihypertensive treatment use, diabetes 
status and smoking status
http://my.americanheart.org/cvriskcalculator
Reynold’s risk score Age, smoking status, systolic BP, TC, hsCRP, family 
history of premature CVD
http://www.reynoldsriskscore.org/
Multi-Ethnic Study of 
Atherosclerosis (MESA) 
10-year CHD risk
Gender, age, CAC, ethnicity, diabetes status, smoking 
status, family history of CVD, TC, HDL-C, systolic BP, 




MESA arterial age 
calculation from CAC score
CAC score, age, ethnicity https://statcoder.wordpress.com/2011/07/27/mesa-
arterial-age-from-coronary-calcium-score/
UKPDS Risk Engine (non-
insulin dependent diabetes)†
Age, duration of diabetes, HbA1c, systolic blood 
pressure, gender, TC, HDL-C, ethnicity, smoking status
https://www.dtu.ox.ac.uk/riskengine/download.php
Diagnosis of FH Gender, age, presence of atherosclerosis, lipid-lowering 
medication use, clinical examination results, known 
DNA mutation, family history
http://www.circl.ubc.ca
An app (FH Diagnosis) is also available from the 
FH foundation: https://itunes.apple.com/us/app/
fh-diagnosis/id543676258?mt=8
TC = total cholesterol; HDL-C = high-density lipoprotein cholesterol; BP = blood pressure; CVD = cardiovascular disease; BMI = mody mass index; ESC = 
European Society of Cardiology;  AHA/ACC = American Heart Association/American College of Cardiology; hsCRP = high-sensitivity C-reactive protein; 
CHD = coronary heart disease; CAC = coronary artery calcification; UKPDS = UK Prospective Diabetes Study; HbA1c = glycated haemoglobin; FH = 
familial hyperholesterolaemia.
*The SA Heart application is based on these guidelines and it is recommended that clinicians refer to this risk score when corresponding with funders in SA. 
†Risk calculators based on equations from the Framingham Heart Study tend to underestimate risks for people with diabetes, as this study included 
relatively few diabetic subjects. The UKPDS Risk Engine is a type 2 diabetes-specific risk calculator based on 53 000 patient years of data from the UKPDS, 
which also provides an approximate margin of error for each estimate.
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Dietary recommendations to lower low-density lipoprotein cholesterol and improve the overall lipoprotein profile
Preferred foods – eat regularly Use in moderation  
(1 - 3 times per week)
Best to avoid these foods (at most 




(minimum 5 portions 
per day)
Raw and cooked vegetables
Choose colourful vegetables
Avocado, butternut, broccoli, cabbage, carrot, beetroot, 
green beans, peppers, pumpkin, spinach and other 
green leafy vegetables and herbs, tomatoes, etc.
Note: no added sugar and/or fat
Potato, sweet potato 
Note: no added sugar 
and/or fat
Vegetables prepared in oil, fat, butter 
or cream
Deep fried potatoes (‘slap chips’), 
potato crisps
Fresh or frozen fruits (no added sugar) Dried fruit, canned 
fruit (in natural juice)
Canned fruit (in sugar syrup), fruit 




Brown/wild rice, buckwheat, barley, bulgur, quinoa, 
millet, whole-wheat couscous, cracked wheat, samp, 
oats, corn, whole spelt, unrefined maize meal, whole-
grain breakfast cereal (with no added sugar), brown 
and whole-wheat bread, seed bread, popcorn (without 
added fat and/or sugar)
Wholewheat breakfast 
cereal with fibre 
and no added sugar, 
wholewheat pasta
Products made with white flour and 
added fat, such as pastries, muffins, 
pies, croissants, white bread, pasta, 
koeksisters, cake, biscuits, cookies, 
crackers, etc.
Breakfast cereal with added sugar, 
breakfast cereal with no fibre, white 
rice
Snacks high in fat, sugar and/or salt
Fast foods high in fat, suagr and/or salt
Legumes Lentils, all dried beans (e.g. small white beans, haricot 
beans, Borlotti beans, black beans, Cannellini beans, 
sugar beans, red kidney beans, fava beans, black-eye 
beans, dhal beans, pinto beans, dried peas, chickpeas, 
canned baked beans, soybeans, cowpeas)
Soybean products 
with high salt content
Meat, chicken and 
fish
Lean fish (hake, kingklip, etc.) 





Lean cuts of beef, lamb, 
pork or veal, seafood, 
shellfish
Lean cuts of cold meats
Liver (limit to 60 
gram per week)
Sausages, salami, polony, bacon, spare 
ribs, hot dogs, organ meats, processed 
meat, skin of chicken, any fat on meat
Dairy food and eggs Low-fat or fat-free dairy: 
Skim milk and fat free yoghurt (unsweetened)
Low-fat milk and low-fat yoghurt (unsweetened)
Fat-free and low-fat cheese, e.g. fat-free and low-fat 
cottage cheese 
Eggs Regular cheese like cheddar, gouda, 
cream, whole milk and full cream 
yoghurt 
Nuts and seeds All (except coconut), 
unsalted 




Dietary recommendations to lower low-density lipoprotein cholesterol and improve the overall lipoprotein profile
1.  Achieve and maintain ideal body weight.
2.  Eat a variety of foods – preferably fresh, unprocessed foods.
3.  Eat vegetables and fresh fruit every day – at least five portions per day.
4 .  Eat whole wheat products and whole wheat cereal without added sugar.
5.  Eat more legumes.
6.  Eat fish, poultry and low-fat or fat-free dairy products.
7.  Limit the intake of red meat.
8.   Avoid/limit foods that are naturally high in sugar like honey, syrups and fruit juices and foods containing added sugar, fructose or corn 
syrup.
9.  Use oils provided by non-tropical vegetable oil for example  sunflower oil, canola oil, olive oil.
10.  If you use alcohol, do so in moderation (men: 2 standard drinks per day; women: 1 standard drink per day). People with high triglyceride 
levels should abstain.
11.  Drink sufficient clean, safe water in preference to carbonated drinks and fruit juices.
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Dietary recommendations to lower low-density lipoprotein cholesterol and improve the overall lipoprotein profile (continued)
Preferred foods – eat regularly Use in moderation  
(1 - 3 times per week)
Best to avoid these foods (at most 
to be chosen occasionally in limited 
amounts)
Cooking fat and 
dressings
Sunflower oil, olive oil, avocado oil, canola oil
Plant stenol-/stanol-enriched soft margarine
Vinegar, mustard, fat-free dressings, tomato sauce 
(low-salt type)
Soft margarines, salad  
dressing, light/lite or 
low-fat mayonnaise
Trans fats and hard margarines, palm, 
palm kernel and coconut oils, butter, 
ghee, lard, beef tallow, beef or mutton 
shin, bacon fat
Limit sweets and 
sweeteners
Non-caloric sweeteners, stevia Cakes, ice creams, fructose, sugar-
sweetened beverages, products 
containing high-fructose corn syrup, 
sugar, sucrose, honey, chocolate, 
candies
Limit intake of salt to  
<5 g (or <2 400 mg 
sodium), equivalent 
to 1 teaspoon) per 
day
Flavour food using:
lemon juice or vinegar;
herbs, e.g. Italian herbs mix, parsley, rosemary, 
oregano, 
spices, e.g. curry powder, paprika, pepper,
 garlic, ginger, chilli, and onions
Salty crackers, bacon, biltong, dried 
sausage
Note: Do not use salt or salty 
condiments at table
Cooking procedures Grilling, boiling, steaming, stirfrying (use allowed oils)
Use less salt when cooking
Roasting Frying, baking in fat and oil
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Consider if statin-attributed muscle symptoms favour statin continuation/reinitiation
Symptomatic & CK <4X ULN  CK ≥4 x ULN without rhabdomyolysisb  Rhabdomyolysis suspected
c
 and/or CK >10 x ULN with
no obvious precipitating
cause, e.g., recent strenuous









1. Low-dose third ecacious (potent)* statin
2. Ecacious* statin with alternate day or 
    once/twice weekly dosing regimen
Aim: Achieve LDL-C goal with maximally tolerated dose of statin
Ezetimibe
Add bile acid absorption inhibitor if available Add brate (not gembrozil) Add PCSK9 inhibitor
If still not at goal: Refer to specialist
6-week washout 




Consider permanently discontinuing 
statin and refer
1. Low-dose second ecacious* statin
2. Ecacious* statin with alternate day or 
once/twice weekly dosing regimen
Symptoms recur 














































CK: creatine kinase; LDL-C: low density lipoprotein cholesterol; ULN: upper limit of the normal range 
 
*efficacious statin such as atorvastatin or rosuvastatin 
a. Where muscle symptoms do not improve after statin discontinuation, causality is uncertain. Withdrawal of statin therapy followed by one 
or more re-challenges (after a washout) can often help in determining causality.      
b. In patients with CK >10 x ULN for which no secondary cause can be found, statin therapy should be discontinued because of potential 
risk of rhabdomyolysis. If CK level subsequently returns to normal, re-challenge with a lower dose of an alternative statin and careful 
monitoring of symptoms and CK may be considered.      
c. Rhabdomyolysis should be considered if there is severe muscular pain, general weakness and signs of myoglobinaemia or myoglobinuria. 
If rhabdomyolysis is suspected statin should not be reintroduced and patient should be referred for evaluation of renal damage.       
 
Recommendations adapted from: Stroes ES, Thompson PD, Corsini A, et al. Statin-associated muscle symptoms: impact on statin therapy – 




Figure 2. General management recommendations for muscle symptoms on statin treatment  
Consider if statin-attributed muscle symptoms favour statin continuation / reinitiation 
Symptomatic & CK <4 x ULN CK !4 x ULN without rhabdomyolysisb 




symptoms Symptoms persist:  
statin re-challengea 
Symptoms improve: 




1) Low dose third efficacious (potent)* statin; 
2) Efficacious* statin with alternate day or 
once/twice weekly dosing regimen 
1) Low dose second efficacious* statin; 
2) Efficacious* statin with alternate day or 
once/twice weekly dosing regimen 
Aim: Achieve LDL-C goal with maximally tolerated dose of statin 
Ezetimibe 
Add bile acid absorption inhibitor 
if available 
Add fibrate (not gemfibrozil) Add PCSK9 inhibitor 
If still not at goal: refer to specialist  
Symptoms recur or 
CK elevation persists 
Refer 
Rhabdomyolysis suspectedc 
and/or CK >10 x ULN with 
no obvious precipitating 
cause, e.g., recent strenuous 
unaccustomed exercise 
Consider permanently 
discontinuing statin and refer 
CK = creatine kinase; LDL-C: low-density lipoprotein cholesterol; ULN = upper limit of the normal range.
* Efficacious statin, such as atorvastatin or rosuvastatin.
a Where muscle symptoms do not improve after statin discontinuation, causality is uncertain. Withdrawal of statin therapy followed by one or more re-
challenges (after a washout) can often help in determining causality.
b In patients with CK >10× ULN for which no secondary cause can be found, statin therapy should be discontinued because of potential risk of rhabdomyolysis. 
If the CK level subsequently returns to normal, re-challenge with a lower dose of an alternative statin and careful monitoring of symptoms and CK may be 
considered.
c Rhabdomyolysis should be considered if there is severe muscular pain, general weakness and signs of myoglobinaemia or myoglobinuria. If rhabdomyolysis 
is suspected, statin should not be reintroduced and patient should be referred for evaluation of renal damage.
Recommendations adapted from: Stroes ES, Thompson PD, Corsini A, et al. Statin-associated muscle symptoms: impact on statin therapy –
European Atherosclerosis Society Consensus Panel Statement on assessment, aetiology and management. Eur Heart J 2015;36(17):1012-
1022. http://dx.doi.org/10.1093/eurheartj/ehv043.[121]
Appendix 5
General management recommendations for muscle symptoms on statin treatment
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